VJOncology Podcast

In this week’s VJOncology podcast, we mark Bladder Cancer Awareness Month by exploring recent advances in bladder cancer research and clinical care. Join Joaquim Bellmunt of Dana-Farber Cancer Institute, Boston, MA, Eva Compérat of Medical University of Vienna, Vienna, Austria, Roberto Contieri of Humanitas University, Milan, Italy, and Vadim Koshkin of University of California, San Francisco, CA, as they discuss circulating tumor DNA for MRD monitoring in muscle-invasive bladder cancer, advances in intravesical therapies and urinary tract diagnostics, de-escalated approaches for low-grade non-muscle-invasive disease, and the evolving molecular classification of bladder cancer into luminal and basal subtypes.

In this week’s VJOncology podcast, we bring you key updates from the 2026 AACR meeting across early-phase immuno-oncology and targeted therapy. Join leading experts Bruno Bockorny, Beth Israel Deaconess Medical Center, Boston, MA, Byoung Chul Cho, Yonsei University, Seoul, South Korea, Kristen Pauken, and Timothy Yap, MD Anderson Cancer Center, Houston, TX, as they discuss the clinical challenges of immune-related adverse events with checkpoint inhibitors, early signals from first-in-human studies of PLN-101095 in refractory solid tumors, emerging safety and activity data from a Phase I dose-escalation study of denikitug, and updated results of elisrasib monotherapy in previously treated KRAS G12C-mutant non-small cell lung cancer.

In this week's instalment of the VJOncology podcast, we examine the rapidly evolving treatment landscape of advanced non-small cell lung cancer, drawing on expert insights from ELCC 2026. This episode spans the breadth of precision oncology in NSCLC: from the clinical challenges of rare actionable alterations and emerging targeted agents, to the growing complexity of first-line treatment sequencing, and the arrival of a promising new immunotherapy class in thoracic oncology. Leading clinicians and researchers from the Jules Bordet Institute, Princess Margaret Cancer Centre, Institut Curie, and Lausanne University Hospital discuss BRAF non-V600E mutations, KRAS G12C, HER2-mutant disease, EGFR exon 20 insertions, amivantamab-based combinations, and the evolving role of bispecific T-cell engagers in NSCLC and mesothelioma. This episode provides actionable insight for clinicians navigating an increasingly crowded and competitive treatment landscape in advanced NSCLC.

In this week’s VJOncology podcast, we mark Head and Neck Cancer Awareness Month by exploring recent advances in head and neck cancer. Join Kevin Harrington, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, Takeshi Kodaira, Aichi Cancer Center, Nagoya, Japan, Andreas Dietz, University Hospital of Leipzig, Leipzig, Germany, and Nabil Saba, Emory University, Atlanta, GA, as they discuss key clinical trial updates, including OrigAMI-4, ASPEN-04, CompARE, and JCOG1912, alongside evolving strategies optimizing radiation dosing, reducing late toxicities, and improving management of recurrent respiratory papillomatosis.

In this week’s VJOncology podcast, we had the opportunity to attend the 2026 British Thoracic Oncology Group (BTOG) conference, where we explored key developments in lung cancer screening, diagnostics, and clinical research. Join Robert Rintoul, University of Cambridge, Cambridge, UK, Lauren Dixon, London School of Hygiene & Tropical Medicine, London, UK, Mariana Brandao, Jules Bordet Institute, Brussels, Belgium, and Anna Bibby, North Bristol NHS Trust, Bristol, UK as they discuss national screening updates, insights from the State of the Nation report, ongoing EORTC trials, and the clinical implications of incidental findings in lung cancer screening programs.

In this week’s VJOncology podcast, we had the opportunity to attend the 12th Immunotherapy of Cancer (ITOC) Conference, where we explored cutting-edge developments in cancer immunotherapy and tumor biology. Join David Giles of Washington University in St. Louis, MO, Bernard Fox of Providence Cancer Institute, Portland, OR, and Krijn Dijkstra of Netherlands Cancer Institute, Amsterdam, Netherlands as they discuss innovative approaches including live cell and dark antigen vaccines, adoptive cell therapy in melanoma, and tumor-intrinsic mechanisms shaping immune exclusion in colorectal cancer.

In this week’s VJOncology podcast, we will be covering highlights from ASCO GU 2026 in San Francisco, CA. Dive into the latest advancements in genitourinary cancers, including groundbreaking trial results and emerging treatment strategies. In this episode, join Enrique Gallardo, MD, Parc Taulí University Hospital, Barcelona, Spain, Jan-Jaap Mellema, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, Pooja Ghatalia, MD, Fox Chase Cancer Center, Philadelphia, PA, Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, and, Aly-Khan Lalani, MD, McMaster University, Hamilton, Canada, as they discuss critical findings from ASCO GU 2026, including combination therapies, innovative approaches to bladder preservation, and novel biomarkers in prostate and renal cell carcinoma.

In this week’s VJOncology podcast, as part of Oesophageal Cancer Awareness Month in the UK, we are pleased to bring you the latest advances shaping the treatment landscape for oesophageal and gastroesophageal cancers. Join leading experts Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, Berend van der Wilk, MD, Erasmus MC Cancer Institute, Kohei Shitara, MD, National Cancer Center Hospital East, and Ian Chau, MD, Royal Marsden Hospital, as they discuss pivotal data from key clinical trials across the disease spectrum. Our expert panel highlights how these data are refining first-line strategies, informing organ-preserving approaches, and advancing biomarker-driven therapies in oesophageal and gastroesophageal cancers.

In this week’s VJOncology podcast, we are delighted to bring you the latest advances in circulating tumor DNA (ctDNA)-informed monitoring and follow-up strategies in breast cancer. Join leading experts Wolfgang Janni, MD, University of Ulm, Ulm, Germany, Arielle Medford, MD, Massachusetts General Cancer Center, Boston, MA, Seth Wander, MD, PhD, Massachusetts General Hospital, Boston, MA, and Rinath Jeselsohn, MD, Dana-Farber Cancer Institute, Boston, MA, as they explore cutting-edge data from key studies including SURVIVE, LEADER, a Phase I/II trial of vepdegestrant, and PACE. Together, they discuss the evolving role of circulating tumor DNA in detecting molecular relapse, guiding early intervention strategies, monitoring treatment response, and predicting resistance across early and advanced ER+/HER2-negative and HR+/HER2-negative breast cancer settings.

In this week’s VJOncology podcast, we bring you key updates on the evolving landscape of checkpoint inhibition beyond PD-1 and PD-L1 across solid tumors. Join leading experts Jesus Fuentes-Antras, MD, NEXT Oncology Madrid, Madrid, Spain, Laurence Buisseret, MD, PhD, Institute Jules Bordet, Brussels, Belgium, and Yuxiang Ma, MD, PhD, Sun Yat-Sen University Cancer Center, Guangzhou, China, as they discuss novel bispecific and bifunctional immunotherapy strategies, first-in-human and early-phase clinical data, and emerging checkpoint inhibitor–ADC combinations shaping treatment paradigms in breast cancer, urothelial carcinoma, and other advanced malignancies.

In recognition of Cervical Cancer Awareness Month, this episode of VJOncology podcasts explores advances in cervical cancer prevention and treatment. We hear from three leading experts who discuss pivotal developments shaping clinical practice. Dr Domenica Lorusso from Fondazione IRCCS National Cancer Institute of Milan examines the breakthrough combination of immunotherapy and radiotherapy in locally advanced disease, highlighting practice-changing data from the KEYNOTE-A18 trial that established pembrolizumab plus chemoradiotherapy as the new standard of care for stage 3 cervical cancer. Dr Amanda Psyrri from National Kapodistrian University of Athens underscores the critical role of HPV vaccination in preventing not only cervical cancer but also HPV-associated oropharyngeal malignancies, particularly those caused by high-risk subtypes 16 and 18. Finally, Dr Alberto Farolfi from IRCCS Istituto Romagnolo per lo Studio dei Tumori shares real-world evidence on the addition of bevacizumab to pembrolizumab-chemotherapy regimens in advanced cervical cancer, demonstrating survival benefits without increased serious adverse events. This episode offers essential insights into the evolving landscape of cervical cancer management from prevention through advanced disease.

This podcast is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Takeda (Gold) and Gilead Sciences (Silver). Supporters have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given. This VJOncology podcast explores the evolving landscape of immunotherapy in gastrointestinal malignancies, spanning from perioperative to adjuvant settings across multiple tumor types. Findings from the Phase II KEYSTEP-008 platform trial are presented, focusing on optimizing pembrolizumab-based combinations in MSI-high, mismatch repair deficient metastatic colorectal cancer. In addition, emerging biomarkers for immunotherapy beyond microsatellite instability in colorectal cancer are explored, including results from the TAPUR trial evaluating dual checkpoint inhibition in patients with BRCA1/2 alterations. The historically challenging adjuvant setting in hepatocellular carcinoma is examined through insights from the KEYNOTE-937 trial evaluating immunotherapy after curative-intent treatment. Finally, experts discuss the NEOSUMMIT-01 trial and how perioperative immunotherapy is transforming treatment strategies for locally advanced gastric and gastroesophageal junction cancers. Together, these perspectives highlight immunotherapy's expanding therapeutic potential across the GI cancer spectrum.

In this week’s VJOncology podcast, we bring you key developments in novel approaches in immunotherapy refractory head and neck cancer. Join head and neck cancer expert Amanda Psyrri, MD, PhD, FACP, National Kapodistrian University of Athens, Athens, Greece, as she discusses on mechanisms of resistance to checkpoint inhibitors, strategies to overcome resistance such as antibody drug conjugates (ADCs) and tumor vaccines, as well as the trials assessing anti-TIGIT inhibitors.

In this week’s VJOncology podcast, the first of 2026, we bring you key updates in the use of artificial intelligence (AI) in oncology and how it will impact clinicians and patients alike. Join renowned experts Anita Grigoriadis, PhD, King’s College London, London, UK, Rosalind Picard, ScD, MIT Media Lab, Cambridge, MA, Jana Lipkova, PhD, University of California, Irvine, CA, and Roberto Salgado, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia as they comment on how to increase AI literacy for oncologists, identifying patients with high-risk lobular breast cancer with AI, and more.

In this episode of the VJOncology Podcast, we bring you key highlights from the San Antonio Breast Cancer Symposium 2025 (SABCS 2025). This curated episode features expert insights into practice-changing data across HER2-positive metastatic disease, hormone receptor–positive early breast cancer, and the growing role of artificial intelligence in risk stratification. Leading investigators discuss advances in targeted therapies, endocrine treatment optimization, and AI-driven tools that may refine prognostic assessment and clinical decision-making in breast cancer.

In this week’s VJOncology podcast, we will be covering highlights from ESMO 2025 in Berlin, Germany. Gain expert insights in the field of genitourinary cancers, including highly-anticipated trial results, emerging biomarkers in kidney cancer, and the evolving role of radionuclides in  prostate cancer. Join renowned speakers Andrea Necchi, MD, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, Sara Coca Membribes, MD, Barts Health NHS Trust, London, UK, Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, Paul Nguyen, MD, MBA, Dana-Farber Cancer Institute, Boston, MA, as they discuss trials such as GDFather-NEO, CALYPSO, and more.

In this week’s VJOncology podcast, we have the pleasure to bring you key updates in gastrointestinal cancer at ESMO 2025, which we attended live in Berlin. Join esteemed experts Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, Michele Reni, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, and Anwaar Saeed, MD, University of Pittsburgh, Pittsburgh, PA, as they discuss ground-breaking trials such as FORTITUDE-101, CASSANDRA, STELLAR-303, and more.

In this episode of the VJOncology Podcast, we bring you four standout interviews from ESMO 2025 that are reshaping the way we think about lung cancer. From antibody-drug conjugates and bispecific T-cell engagers through novel HER2-targeted TKIs to tumour-immune microenvironment biomarkers, the treatment paradigm is evolving rapidly. Join us as we explore findings from the Phase III OptiTROP-Lung04 study of sacituzumab tirumotecan in EGFR-mutant non-small-cell lung cancer (NSCLC) post-TKI progression, safety analysis of DeLLphi-304: tarlatamab vs standard chemo in small-cell lung cancer (SCLC), the first-line Beamion LUNG-1 experience of zongertinib in advanced HER2-mutant NSCLC and biomarker insights from the ImmunoDriver-2 analysis. We’ll weave together how these advances hint at a future where molecular and immunologic profiling come together: identifying patients who will benefit most, integrating new treatment classes, and navigating safety/survivorship in more complex regimens. 

In this week’s podcast from VJOncology, leading experts share key insights from the 44th Congress of the European Society of Surgical Oncology (ESSO 44), held in Gothenburg, Sweden. The meeting brought together global specialists to discuss innovations in cancer surgery, including artificial intelligence, robotics, and fluorescence imaging. Beate Rau, MD, PhD, highlights advances across gastrointestinal and rectal cancers, as well as the role of intraperitoneal chemotherapy in gastric cancer. Marco Fiore, MD, discusses the evolving surgical approach to retroperitoneal sarcoma, while Piotr Rutkowski, MD, explores progress in melanoma management, from gene expression profiling to new targeted treatments. Gabrielle van Ramshorst, MD, outlines the essential skills for the next generation of colorectal surgeons, and Domenico D’Ugo, MD, reflects on the concept of the mesogastrium and its implications for radical gastric cancer surgery.

In this week’s VJOncology podcast, leading experts share the latest updates in ADCs in HER2-positive and metastatic breast cancer in recognition of Breast Cancer Awareness Month. Charles Geyer, MD, discusses pivotal results from the Phase III DESTINY-Breast05 trial, where trastuzumab deruxtecan (T-DXd) significantly improved invasive disease-free and disease-free survival versus trastuzumab emtansine (T-DM1) in high-risk HER2-positive early breast cancer, reducing the risk of brain metastases. Sara Tolaney, MD, MPH, highlights the practice-changing reduction in recurrence risk with T-DXd and comments on the expanding role of antibody–drug conjugates (ADCs) in earlier lines of therapy across breast cancer subtypes, referencing data from DESTINY-Breast09 and ASCENT-03. Finally, Erika Hamilton, MD, reviews the advancement of ADCs into the curative setting through DESTINY-Breast11 and discusses emerging combination strategies and first-line use in triple-negative breast cancer, emphasizing the growing importance of ADCs in modern breast cancer care.

In this week’s VJOncology podcast, leading experts share key updates presented at the ESMO 2025 Congress in Berlin, Germany. Sara Tolaney, MD, MPH, highlights the expanding role of ADCs in earlier lines of metastatic breast cancer, presenting data from the DESTINY-Breast09 and ASCENT-03 trials, and discusses results from DESTINY-Breast05, where trastuzumab deruxtecan demonstrated superior outcomes to trastuzumab emtansine in high-risk HER2-positive early breast cancer. Scott Tagawa, MD, reports findings from the PSMAddition trial of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer, showing improved radiographic progression-free survival. Antonio Passaro, MD, PhD, outlines data from the OptiTROP-Lung04 study of sacituzumab tirumotecan in EGFR-mutated NSCLC, establishing a new benchmark for TROP2-directed ADCs. Andrea Necchi, MD, discusses interim results from the RC48-C016 trial supporting disitamab vedotin plus toripalimab in HER2-expressing urothelial carcinoma, and Sapna Patel, MD, shares encouraging early findings on PRAME-directed TCR therapy in uveal melanoma.

In this week’s VJOncology podcast, leading experts share the latest updates in the management of hepatocellular carcinoma (HCC) in recognition of Liver Cancer Awareness Month. Stephen Lam Chan, MD, FRCP, discusses emerging immunotherapy and targeted approaches, including novel TIM3 and TIGIT inhibitors, and findings from the SIERRA study of durvalumab and tremelimumab in advanced HCC. Lorenza Rimassa, MD, reviews the CheckMate 9DW trial establishing nivolumab plus ipilimumab as a new standard of care, while Qi Cheng, PhD, highlights promising results from a Phase II study of irpagratinib plus atezolizumab in FGF19-positive HCC. Ciro Celsa, MD, PhD, shares real-world data from the DT-REAL study evaluating durvalumab with or without tremelimumab in unresectable HCC, confirming the regimen’s effectiveness in clinical practice. Finally, Marina Baretti, MD, presents encouraging findings from a Phase I study of a peptide vaccine targeting the DNAJB1-PRKACA fusion in fibrolamellar HCC.

In this week’s VJOncology podcast, we are joined by brain tumor experts Stephen Bagley, MD, MSCE, University of Pennsylvania, Philadelphia, PA, and Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, as they discuss the latest updates in cerebrospinal fluid (CSF) liquid biopsies in brain tumors. They will comment on the rationale and challenges in CSF liquid biopsies in this space, current research in their clinical utility and what the future holds for this area.

In this week’s exclusive VJOncology podcast, we are joined by Javier Martín-Broto, MD, PhD, Fundación Jiménez Díaz University Hospital, Madrid, Spain, who shares expert insights on the evolving role of immunotherapy in sarcoma. He discusses the unique immunosensitivity of alveolar soft part sarcoma, the potential of combining checkpoint inhibitors with anti-angiogenic or anti-CTLA-4 agents, and encouraging results with TCR-T cell therapy in synovial sarcoma and myxoid liposarcoma. The role of biomarkers such as tertiary lymphoid structures (TLS) is also highlighted as a predictor of response to immunotherapy.

In this week’s VJOncology podcast, we have the pleasure to bring you key updates in lung cancer at IASLC 2025 World Conference on Lung Cancer (WCLC), which we attended live in Barcelona, Spain. Join experts John Varlotto, MD, Marshall University, Huntington, WV, Alessio Cortellini, MD, Bio-Medico University, Rome, Italy, Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, Nicolas Girard, MD, Institut Curie, Paris, France, and Kenneth O'Byrne, MD, MB, BCh, Princess Alexandra Hospital, Brisbane, Australia, as they discuss pivotal trials in non-small cell lung cancer (NSCLC) such as the FLAURA2, and ACROSS 2 trials, developments in mesothelioma, and practice-changing data in small cell lung cancer (SCLC).

In this week’s podcast from VJOncology, three leading experts provide insights into the latest advances in precision medicine for head and neck cancer. Luigi Lorini of Humanitas Research Hospital discusses the evolving treatment landscape of immunotherapy in head and neck squamous cell carcinoma. Danny Rischin of the Peter MacCallum Cancer Centre presents findings from a Phase II trial evaluating fianlimab plus cemiplimab in patients with recurrent or metastatic PD-L1–expressing head and neck squamous cell carcinoma. Finally, Jun Ma from Sun Yat-sen University Cancer Center explores the future of immunotherapy in nasopharyngeal carcinoma beyond PD-1 and shares results from the Phase III DIAMOND trial of toripalimab with induction chemotherapy and radiotherapy, with or without concurrent cisplatin, in locoregionally advanced disease.

In this week’s VJOncology podcast, we will be joined by Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, as he outlines current and emerging strategies for managing HER2-positive metastatic breast cancer after antibody–drug conjugate (ADC) therapy, with a focus on trastuzumab deruxtecan (T-DXd). He discusses the use of tucatinib-based regimens, mechanisms of resistance to agents such as trastuzumab emtansine (T-DM1), and approaches to treating brain metastases, drawing on evidence from trials. The importance of individualized treatment is highlighted, particularly in hormone receptor–positive disease, where CDK4/6 inhibitors may provide added benefit.

In this week’s installment of the VJOncology podcast, we will examine the cutting-edge applications of artificial intelligence in clinical oncology. This episode presents a curated series of expert insights into AI-driven tools for early detection, diagnostic precision, biomarker development, treatment guidance, and prognostic assessment. Leading clinicians and researchers discuss breast, sarcoma, kidney, gastric, and lung cancers, highlighting how AI is being integrated into clinical workflows, risk stratification, and patient-specific decision-making. This episode provides actionable knowledge on leveraging AI to improve diagnostic accuracy, optimize therapeutic strategies, and enhance patient outcomes across multiple tumor types.

Join leading GI cancer experts J. Randolph Hecht, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, Jasmine Mitchell, UCLA Santa Monica Medical Center, Santa Monica, CA, and Jingran Ji, UCLA Santa Monica Medical Center, Santa Monica, CA, as they share key insights from the most impactful gastrointestinal cancer updates presented at ASCO 2025. In this episode, they discuss pivotal trials including CHALLENGE (NCT00819208), demonstrating that structured exercise can improve disease-free survival in resected colon cancer; ATOMIC (NCT02912559), highlighting the role of adjuvant immunotherapy with atezolizumab in MSI-high colon cancer; and MATTERHORN (NCT04592913), where adding durvalumab to perioperative FLOT improved outcomes in gastric and gastroesophageal junction adenocarcinoma.

In this week's VJOncology podcast, we will be covering highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 in Chicago, IL. Gain expert insight on exploratory biomarkers, treatment landscape shifts, and practice-changing trials from leading researchers in the field of genitourinary cancers. Join renowned speakers Angela Jia, Tian Zhang, Michael Harrison, Margaret Gatti-Mays, and Stefanie Zschaebitz, as they discuss Phase I/II trial results on neoadjuvant combination therapy for cisplatin-ineligible bladder cancer, and strides in personalized vaccines in metastatic prostate cancer.  

In this episode of the VJOncology podcast, we explore the evolving landscape of gynecologic cancer care with expert insights recorded at the 2025 ESMO Gynaecological Cancers Congress in Vienna. Ilana Cass, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, discusses new data from the RUBY trial and the impact of dostarlimab in endometrial cancer. Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, presents findings from the TRUST trial, highlighting the value of primary debulking surgery in advanced ovarian cancer. We also hear from Felix Hilpert, MD, Krankenhaus Jerusalem, Hamburg, Germany on overcoming treatment hesitancy in elderly ovarian cancer patients, and Angeles Secord, MD, Duke Cancer Institute, Durham, NC shares promising results from the PICCOLO study of mirvetuximab soravtansine in FRα-positive disease. Finally, Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, outlines a new standard of care for stage 3 cervical cancer, combining radiotherapy with pembrolizumab as supported by KEYNOTE-A18. Tune in for expert commentary and clinical implications that could shape the future of gynecologic oncology.

In this weeks podcast from VJOncology, five leading experts share updates and insights on the evolving landscape of precision medicine in sarcoma. Robin Jones discusses the complexities of implementing precision medicine and presents results from a Phase III trial of catequentinib in advanced leiomyosarcoma. Javier Martín-Broto explores recent advances in immunotherapy and shares findings from Cohort 7A of the ImmunoSarc2 trial, evaluating epirubicin and ifosfamide plus nivolumab in undifferentiated pleomorphic sarcoma. Nadia Hindi highlights Cohort 2, which assessed sunitinib and nivolumab in extraskeletal myxoid chondrosarcoma. Ramya Ramaswami addresses unmet needs in Kaposi sarcoma and presents data from a Phase I trial of efineptakin alfa in patients with and without HIV. Finally, Brian Van Tine discusses a Phase II trial of olaparib and temozolomide in advanced uterine leiomyosarcoma.

In this weeks VJOncology podcast, we have the pleasure to bring you key updates in CAR-T and cellular therapies in brain tumors. Gain expert insights on landmark trials, treatment advances, and shifting screening practices from some of the foremost voices in the field. Topics of discussion include a Phase I trial of intracranial B7H3-directed CAR-T cell therapy in patients with recurrent glioblastoma, effective strategies in anti- glioblastoma CAR-T cells, and dendritic cell therapy in recurrent glioblastoma.

This week’s VJOncology podcast episode highlights four breakthrough studies from ESMO GI 2025 in Barcelona, Spain, featuring expert insights on gastrointestinal cancer advances. Coverage includes the EXPEL PANC study combining BXCL701 with pembrolizumab for pancreatic cancer, SIERRA study safety data on the STRIDE regimen for hepatocellular carcinoma, TALENTACE trial results combining TACE with atezolizumab plus bevacizumab, and updated MATTERHORN study data on perioperative immunotherapy for gastric cancer. Leading oncologists share perspectives on these game-changing developments reshaping GI cancer treatment live from Barcelona, Spain.

Join esteemed experts Joao Victor Alessi, Hospital Sírio-Libanês, Sao Paolo, Brazil, and Alessandro Di Federico, Dana-Farber Cancer Institute, Boston, MA, as they discuss the most anticipated updates in lung cancer presented at ASCO 2025, as they comment on ground-breaking trials and provide their insights on the significance of the findings and updates. In this episode, they comment on the potential of new agents like tarlatamab, and pivotal trials such as the OptiTROP-Lung03 trial of sacituzumab tirumotecan in EGFR-mutated non-small cell lung cancer (NSCLC), the CheckMate 816 trial of neoadjuvant nivolumab plus chemotherapy, and the ALNEO trial of alectinib in ALK-positive NSCLC.

Join our experts as they delve into the latest advancements in breast cancer presented at ASCO 2025, as they comment on highly anticipated trials and gives their perspectives on the significance of the findings and updates. In this episode, Kevin Kalinsky, Emory University Hospital, Atlanta, GA, and Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY, receive updates on trials presented at this year’s ASCO, including the ASCENT-04 trial (NCT05382286) of sacituzumab govitecan and pembrolizumab in PD-L1-positive triple-negative breast cancer (TNBC) and the DESTINY-Breast09 trial (NCT04784715) of first-line trastuzumab deruxtecan (T-DXd) and pertuzumab in patients with HER2+ breast cancer.

In this weeks VJOncology podcast, we have the pleasure to bring you key updates in gynecological cancer from ASCO 2025, which we attended live in Chicago, IL. Join leading experts as they comment on key trials and provide their insights on the ever-evolving treatment landscape and screening patterns.   Dr Jyoti Mayadev gives an overview of highly anticipated trials at the conference including the CALLA, OUTBACK and KEYNOTE-A18 trials, and Dr Shannon Westin discusses findings from the ctDNA findings from the DUO-E trial in endometrial cancer. Dr Kamran Ahmed comments on the efficacy of SBRT followed by atezolizumab in cervical cancer, and Dr Ritu Salani provides results of the TroFuse-020 trial of sacituzumab tirumotecan in pre-treated cervical cancer.

In this ASCO 2025 edition of VJOncology podcasts, we spotlight five game-changing studies set to reshape cancer care across multiple tumor types. Join our host and a panel of leading oncology experts as they unpack the most impactful data from this year’s American Society of Clinical Oncology Annual Meeting. Discover pivotal insights from the MATTERHORN trial in gastric cancer, explore KRAS G12C-targeted combinations in NSCLC, and delve into resistance-prevention strategies in HR+/HER2– breast cancer with findings from the SERENA-6 trial. We also explore the potential of mRNA-based bispecific antibodies for solid tumors and analyze expanded results from CheckMate 8HW in MSI-high colorectal cancer. With commentary from top investigators including Yelena Janjigian, Alexander Spira, Michael Gnant, Timothy Yap, and Heinz-Josef Lenz, this episode offers essential updates for oncology professionals. Tune in for a concise, expert-led review of the most practice-changing research from ASCO 2025.

Welcome to another episode of the VJ Oncology Podcast, where we bring you the forefront of cancer research and clinical practice. This week, we focus on the revolutionary field of cell therapy for solid tumors, with particular emphasis on lung cancer and melanoma. Join Dr. Alison Betoff-Warner and Dr. Ben Creelan as they discuss the potential of targets like TILs, TCRs, and CAR-Ts. Learn about the challenges posed by IL-2 toxicity and discover the latest developments in emerging trials, including promising advancements in therapies targeting PREM and P53. Don't miss out on these expert insights into the future of cancer treatment, and explore how innovative cell therapy approaches are transforming the landscape of oncology.

In this week’s podcast, we take you through the latest episodes of the VJOncoAlert Journal Club—a collaborative series from VJOncology and OncoAlert that brings together leading oncology experts to discuss the most impactful and practice-changing research in the field. We are joined by Misty Shields, MD, PhD, from the Indiana University Simon Comprehensive Cancer Center in Indianapolis, IN, who discusses the latest updates in small cell lung cancer. Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute in London, UK, and Brian Rini, MD, FASCO, of Vanderbilt-Ingram Cancer Center in Nashville, TN, comment on the health-related quality of life (HRQoL) results from the LITESPARK-005 trial (NCT04195750) in advanced renal cell carcinoma (RCC). Berend J van der Wilk, MD, PhD, from Erasmus MC Cancer Institute in Rotterdam, Netherlands, discusses the SANO trial—a multicenter, non-inferiority, stepped wedge cluster randomized trial investigating active surveillance versus standard resection following neoadjuvant chemoradiotherapy for locally advanced esophageal cancer. Lastly, Luca Arecco, MD, from the University of Genova in Genova, Italy, comments on the prognostic implications of risk definitions from the monarchE (NCT03155997) and NATALEE (NCT03701334) trials Stay tuned for more from the VJOncoAlert Journal Club at VJOncology.com!

Welcome to this week's podcast by VJOncology, where we delve into the latest developments in adjuvant therapy for hepatocellular carcinoma. Join five leading experts as they discuss cutting-edge research and its impact on clinical practices. Stephen Chan, MBBS, MRCP, The Chinese University of Hong Kong, Hong Kong, China, Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS Medical School Singapore, Singapore, and Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, break down the latest research, ongoing clinical trials, and what these developments mean for clinical practice. They touch on the promising results of the IMbrave150 and IMbrave050 trial, the Phase II study of regorafenib and pembrolizumab, the KEYSTEP-004 trial and future prospects for these adjuvant therapies.

In this week's VJOncology podcast, we are focusing again on Prostate Cancer Awareness Month, where we have collaborated with experts on liquid biopsies for tracking and predicting treatment outcomes in metastatic castration-resistant prostate cancer. Join Chinmay Jani from the Sylvester Comprehensive Cancer Centre, Xin Gao from Massachusetts General Hospital Cancer Center, Christos Kyriakopoulos from the University of Wisconsin, Andrew Armstrong from the Duke Cancer Institute, and Susan Halabi from Duke University Medical Center, as they present various trial updates and their exclusive insights from this burgeoning field. 

In this weeks VJOncology podcast, we explore key update from BTOG 2025 in thoracic oncology. Prof. Sanjay Popat discusses the evolving role of ADCs in lung cancer treatment, focusing on efficacy, toxicity management, and biomarker integration. Prof. Samreen Ahmed examines ADC resistance mechanisms, drawing insights from breast cancer therapy to refine drug development strategies. Prof. Robert Rintoul reviews a new UK Lung Cancer Coalition report on genomic testing challenges and strategic solutions for faster diagnostics. Dr Adam Januszewski highlights the complexities of implementing genomics in the UK and the need for a streamlined approach. Prof. Neal Nivani concludes by reflecting on BTOG 2025’s success and NHS England’s new service specification.

In this weeks VJOncology podcast, three oncology experts delve into the transformative potential of liquid biopsy in breast cancer treatment. First, Michail Ignatiadis (Jules Bordet Institute, Brussels, Belgium) discusses the clinical applications and challenges of utilizing liquid biopsy in metastatic breast cancer, focusing on the Phase III TREAT ctDNA trial (NCT05512364) and its implications for ER-positive, HER2-negative cases. Next, Marina Sharifi (University of Wisconsin Carbone Cancer Center, Madison, WI) introduces an innovative fragmentomic analysis of circulating tumor DNA (CT-DNA) to discern estrogen receptor status in metastatic breast cancer, potentially minimizing the need for invasive tissue biopsies. Finally, Guilherme Nader-Marta (Dana-Farber Cancer Center, Boston, MA) shares insights from the PACE trial (NCT03147287), highlighting two pivotal studies that explore biomarkers in ER-positive, HER2-negative metastatic breast cancer and underscore the prognostic value of liquid biopsy in optimizing treatment strategies.   For more updates on breast cancer, be sure to visit our dedicated Breast Cancer Channel.

In this podcast, we will discuss recent developments in radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) treatment, as part one of our series for Prostate Cancer Awareness Month. Listen to leading experts as they share breakthroughs in mCRPC research.   First, Omid Yazdanpanah, MD, from the University of California, shares findings from the VISION trial, which assessed 177Lu-PSMA-617 with or without androgen receptor pathway inhibitors (ARPIs) in patients with mCRPC, as well as the potential of radioligands with ARPIs in in the ENZA-p trial. Andrei Gafita, MD, from Johns Hopkins Medicine, subsequently discusses the significance of post-therapy LuPSMA-SPECT/CT in patients with mCRPC and Umang Swami, MD, MS, from the University of Utah gives an overview of findings from the PRO-XL trial. Michael Morris, from Memorial Sloan Kettering Cancer Center, ends the podcast by addressing the challenges in using radioligand therapy for patients with metastatic castration-resistant prostate cancer.

Join us in this episode as we go through the latest advancements in genitourinary cancer treatment presented at ASCO GU 2025 in San Francisco. Our expert guests provide insights into ground-breaking trials and studies that are reshaping the landscape of cancer therapy. Join Nadine Houede, Xinan Sheng, Nicholas James, and Wenxin Xu, as they discuss highly anticipated updates such as results of neoadjuvant durvalumab with chemotherapy in high-risk high-risk upper tract urothelial carcinoma (UTUC), disitamab vedotin and toripalimab in HER2-expressing bladder cancer, and updates from the STAMPEDE trial. 

Welcome to this week's podcast by VJOncology, where we delve into the emerging trends and challenges in the field of cellular therapies for oncology. Our expert panel includes Leonardo Ferreira (The Medical University of South Carolina, Charleston, SC), who discusses the groundbreaking potential and current obstacles of CAR T cells in treating solid tumors, emphasizing the innovative role of chimeric antigen receptor regulatory T cells. We also hear from Sebastian Klobuch (Netherlands Cancer Institute, Amsterdam, The Netherlands) on the advancements in TIL and TCR-modified therapies. He explores potential ways to mitigate treatment toxicities and expand the applicability of these therapies beyond melanoma. Andrew Furness (Royal Marsden Hospital, London, UK) highlights the promise of TIL therapy for melanoma, while addressing regulatory challenges. Allison Betof Warner (Stanford Cancer Center, Stanford, CA) provides insights into the evolving use of life looser in managing melanoma cases with brain metastases, alongside a specially designed pilot trial to explore treatment safety. Mina Lobbous (Case Western Reserve University, Cleveland, OH) shares updates on gene-modified gamma-delta T cells targeting glioblastoma multiforme, focusing on phase one trial outcomes and future directions for improving patient survival rates.

In this podcast, we explore the latest advancements in the treatment of PD-1 refractory melanoma. This week, we are joined by Allison Betof Warner (Stanford Cancer Center, Stanford, CA) and Omid Hamid (The Angeles Clinic and Research Institute, Los Angeles, CA) and Inderjit Mehmi (The Angeles Clinic and Research Institute, Los Angeles, CA). We will hear about the clinical definitions and significance of PD-1 resistance, including insights from SITC on primary and secondary resistance. The discussion will also highlight the implications for clinical trial design and strategies to overcome resistance in melanoma therapy. Updates on emerging treatment options, including the combination of immunotherapies, promising data from trials involving tumor-infiltrating lymphocytes (TIL) and oncolytic viruses, and recent FDA approvals that are shaping new treatment paradigms, are also discussed. Additionally, future directions in melanoma research, such as engineered T cells and other cellular therapies, and their potential to improve patient outcomes. For more updates on melanoma and skin cancer research, be sure to visit our dedicated Skin Cancer Channel. Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify, and join the conversation via X @VJOncology. Stay tuned for more insights at VJOncology.com.

In this week’s podcast, we will provide updates the emerging roles of circulating tumor DNA (ctDNA) in managing colorectal cancer. We are joined by Michael Brian LaPelusa, MD, University of Texas MD Anderson Cancer Center, Houston, TX; Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina; Anup Kasi, MD, MPH, University of Kansas Cancer Center, Kansas City, KS; Giulia Martini, MD, PhD, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy; and Kanwal Pratap Singh Raghav, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX. The role of ctDNA in predicting treatment responses and assessing minimal residual disease (MRD) will be discussed. Biomarker-driven treatment strategies assessed in the TACT-D, and CAPRI 2-GOIM trials will additionally be evaluated in this week’s podcast.

In this week’s podcast, we will discuss the most recent developments in breast cancer from the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. Join us as renowned experts exclusively speak with us on highly anticipated findings from clinical trials across different breast cancer subtypes. Gaia Griguolo from University of Padova in Italy, first discusses the PATINA trial, which investigated the addition of palbociclib to anti-HER2 and endocrine therapy in HR+/HER2+ breast cancer and Puneet Singh from The University of Texas MD Anderson Cancer Center comments on the COMET trial, which compared active monitoring with surgical management in low-risk ductal carcinoma in situ (DCIS). Elisa Agostinetto from Jules Bordet Institute subsequently gives an overview of findings from the Phase II DECRESCENDO trial of anthracycline-free treatment for HER2-positive, HR-negative, node-negative early breast cancer. Icro Meattini closes this episode with results from the EUROPA and FAST-Forward studies.